ArticleCureus2026
Evaluation of Tissue Adequacy by Computed Tomography-Guided Needle Biopsy for Comprehensive Genomic Profiling Following Chemotherapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Computed tomography-guided needle biopsy (CT-NB) has become increasingly important for comprehensive genomic profiling (CGP). However, factors influencing tissue adequacy for CGP after chemotherapy remain unclear. Purpose This study aimed to evaluate the factors affecting the tissue adequacy of CT-NB specimens for CGP following chemotherapy. Materials and methods We retrospectively reviewed patients who underwent CT-NB for intended CGP after chemotherapy between June 2020 and December 2024. Tissue adequacy was defined as tumor content ≥20% on pathological assessment. Adequacy rates were calculated, and associations with tumor size, number of needle passes, and 18F-fluorodeoxyglucose (FDG) uptake were evaluated. Results This study included 33 patients (median age: 71 years). Biopsy sites were the bone (n=9), liver (n=8), lymph nodes (n=5), and others (n=11). One procedure was technically unsuccessful, and five patients did not proceed to CGP owing to clinical deterioration or other reasons. Among 27 evaluable patients, 17 (63%) provided adequate specimens, whereas 10 (37%) were inadequate owing to insufficient tumor cells. Tissue adequacy was not significantly associated with tumor size or the number of needle passes. Among FDG uptake parameters (n=16), the maximum standard uptake value (SUVmax) showed no significant difference between the adequate and inadequate groups, whereas the mean standard uptake value (SUVmean) demonstrated a statistically significant difference between both groups. Ultimately, the SUVmax/SUVmean ratio showed no significant relationship with tissue adequacy. Conclusion CT-NB can provide tissue for CGP after chemotherapy; however, adequate tissue acquisition remains challenging. In patients with available FDG-PET/CT, a higher SUVmean was associated with tissue adequacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.